-
1
-
-
33748451151
-
Anticancer activities of histone deacetylase inhibitors
-
1:CAS:528:DC%2BD28XptVCltrY%3D 16955068
-
Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 769-784
-
-
Bolden, J.E.1
Peart, M.J.2
Johnstone, R.W.3
-
2
-
-
84874410182
-
Histone deacetylase inhibitors (HDACIs): Multitargeted anticancer agents
-
1:CAS:528:DC%2BC3sXktFCms70%3D 23459471
-
Ververis K, Hiong A, Karagiannis TC, Licciardi PV (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7:47-60
-
(2013)
Biologics
, vol.7
, pp. 47-60
-
-
Ververis, K.1
Hiong, A.2
Karagiannis, T.C.3
Licciardi, P.V.4
-
3
-
-
84873636026
-
Histone deacetylase inhibitors: Novel agents in cancer treatment
-
23372094
-
Glass E, Viale PH (2013) Histone deacetylase inhibitors: novel agents in cancer treatment. Clin J Oncol Nurs 17:34-40
-
(2013)
Clin J Oncol Nurs
, vol.17
, pp. 34-40
-
-
Glass, E.1
Viale, P.H.2
-
4
-
-
67349095775
-
Development of vorinostat: Current applications and future perspectives for cancer therapy
-
1:CAS:528:DC%2BD1MXmsF2jt7k%3D 19181442
-
Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201-210
-
(2009)
Cancer Lett
, vol.280
, pp. 201-210
-
-
Richon, V.M.1
Garcia-Vargas, J.2
Hardwick, J.S.3
-
5
-
-
36148950997
-
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
-
1:CAS:528:DC%2BD2sXhtlOmurrL 17962618
-
Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247-1252
-
(2007)
Oncologist
, vol.12
, pp. 1247-1252
-
-
Mann, B.S.1
Johnson, J.R.2
Cohen, M.H.3
Justice, R.4
Pazdur, R.5
-
6
-
-
84857522968
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
-
1:CAS:528:DC%2BC38XltlaqsrY%3D 22271479
-
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30:631-636
-
(2012)
J Clin Oncol
, vol.30
, pp. 631-636
-
-
Coiffier, B.1
Pro, B.2
Prince, H.M.3
Foss, F.4
Sokol, L.5
Greenwood, M.6
-
7
-
-
77955604540
-
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
-
1:CAS:528:DC%2BC3cXhtVWqu7rL 20649502
-
Watanabe T (2010) Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs 19:1113-1127
-
(2010)
Expert Opin Investig Drugs
, vol.19
, pp. 1113-1127
-
-
Watanabe, T.1
-
8
-
-
78651378094
-
Histone deacetylase inhibitors in Hodgkin lymphoma
-
21127943
-
Buglio D, Younes A (2010) Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs 28(Suppl 1):S21-S27
-
(2010)
Invest New Drugs
, vol.28
, pp. 21-S27
-
-
Buglio, D.1
Younes, A.2
-
9
-
-
83255170966
-
Treatment of relapsed or refractory chronic lymphocytic leukemia
-
Veliz M, Pinilla-Ibarz J (2012) Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control 19:37-53
-
(2012)
Cancer Control
, vol.19
, pp. 37-53
-
-
Veliz, M.1
Pinilla-Ibarz, J.2
-
10
-
-
66149161777
-
Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma
-
1:CAS:528:DC%2BD1MXmtVKlsrw%3D 19417021
-
Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G et al (2009) Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 15:3472-3483
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3472-3483
-
-
Lopez, G.1
Liu, J.2
Ren, W.3
Wei, W.4
Wang, S.5
Lahat, G.6
-
11
-
-
33745087150
-
CRA-024781: A novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo
-
1:CAS:528:DC%2BD28XltVWms7Y%3D 16731764
-
Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L et al (2006) CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5:1309-1317
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 1309-1317
-
-
Buggy, J.J.1
Cao, Z.A.2
Bass, K.E.3
Verner, E.4
Balasubramanian, S.5
Liu, L.6
-
12
-
-
77955960586
-
PCI-24781, a novel hydroxamic Acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells
-
Rivera-Del VN, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M et al (2010) PCI-24781, a novel hydroxamic Acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells. Int J Cell Biol 207420
-
(2010)
Int J Cell Biol
, pp. 207420
-
-
Rivera-Del, V.N.1
Gao, S.2
Miller, C.P.3
Fulbright, J.4
Gonzales, C.5
Sirisawad, M.6
-
13
-
-
77956335478
-
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
-
1:CAS:528:DC%2BC3MXht1ems7Y%3D 20461381
-
Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X et al (2011) Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol 67:439-446
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, pp. 439-446
-
-
Yang, C.1
Choy, E.2
Hornicek, F.J.3
Wood, K.B.4
Schwab, J.H.5
Liu, X.6
-
14
-
-
79956061602
-
Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines
-
1:CAS:528:DC%2BC3MXms1Gktrc%3D 21508354
-
Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X et al (2011) Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res 31:1115-1123
-
(2011)
Anticancer Res
, vol.31
, pp. 1115-1123
-
-
Yang, C.1
Choy, E.2
Hornicek, F.J.3
Wood, K.B.4
Schwab, J.H.5
Liu, X.6
-
16
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group
-
1:STN:280:DyaL3s7kvFOgsw%3D%3D 7165009
-
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
Horton, J.4
Davis, T.E.5
McFadden, E.T.6
-
17
-
-
33947496614
-
Revised response criteria for malignant lymphoma
-
17242396
-
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586
-
(2007)
J Clin Oncol
, vol.25
, pp. 579-586
-
-
Cheson, B.D.1
Pfistner, B.2
Juweid, M.E.3
Gascoyne, R.D.4
Specht, L.5
Horning, S.J.6
-
18
-
-
45149100665
-
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines
-
2972576 1:CAS:528:DC%2BD1cXnsVOktrk%3D 18216293
-
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456
-
(2008)
Blood
, vol.111
, pp. 5446-5456
-
-
Hallek, M.1
Cheson, B.D.2
Catovsky, D.3
Caligaris-Cappio, F.4
Dighiero, G.5
Dohner, H.6
-
19
-
-
84881085302
-
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase i
-
1:CAS:528:DC%2BC3sXpvVyls7k%3D 23790467
-
Fouliard S, Robert R, Jacquet-Bescond A, du Rieu QC, Balasubramanian S, Loury D et al (2013) Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. Eur J Cancer 49:2791-2797
-
(2013)
Eur J Cancer
, vol.49
, pp. 2791-2797
-
-
Fouliard, S.1
Robert, R.2
Jacquet-Bescond, A.3
Du Rieu, Q.C.4
Balasubramanian, S.5
Loury, D.6
-
21
-
-
84939985066
-
BSA-adjusted dose? An old method to fight old bias
-
PAGE Accessed 30-9-2013
-
Fouliard S, Chenel M. BSA-adjusted dose? An old method to fight old bias. Poster presented at the Population Approach Group Europe meeting 2010. PAGE 2010; www.page-meeting.org. Accessed 30-9-2013
-
(2010)
Population Approach Group Europe Meeting 2010
-
-
Fouliard, S.1
Chenel, M.2
-
22
-
-
84880707486
-
A phase II multicenter study of the histone deactelase inhibitor abexinostat (PCI-24781) in relapsed/refractory follicular lymphoma (FLp and mantle cell lymphoma (MCL)
-
Abstract 55
-
Evens AM, Vose JM, Harb W, Gordon LI, Langdon R, Grant B et al. A phase II multicenter study of the histone deactelase inhibitor abexinostat (PCI-24781) in relapsed/refractory follicular lymphoma (FLp and mantle cell lymphoma (MCL). Abstract 55. Blood 2013; 120 (Suppl)
-
(2013)
Blood
, pp. 120
-
-
Evens, A.M.1
Vose, J.M.2
Harb, W.3
Gordon, L.I.4
Langdon, R.5
Grant, B.6
-
23
-
-
84876460347
-
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma
-
3587323 1:CAS:528:DC%2BC3sXjsFKms7Y%3D 23297126
-
Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL et al (2013) Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121:1604-1611
-
(2013)
Blood
, vol.121
, pp. 1604-1611
-
-
Green, M.R.1
Gentles, A.J.2
Nair, R.V.3
Irish, J.M.4
Kihira, S.5
Liu, C.L.6
-
24
-
-
84895815322
-
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma
-
3907271 1:CAS:528:DC%2BC3sXhvFyksbbL 24362818
-
Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C et al (2014) Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46:176-181
-
(2014)
Nat Genet
, vol.46
, pp. 176-181
-
-
Okosun, J.1
Bodor, C.2
Wang, J.3
Araf, S.4
Yang, C.Y.5
Pan, C.6
-
25
-
-
79958084461
-
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
-
3111195 1:CAS:528:DC%2BC3MXntV2hsbg%3D 21559012
-
Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A et al (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104:1828-1835
-
(2011)
Br J Cancer
, vol.104
, pp. 1828-1835
-
-
Munster, P.N.1
Thurn, K.T.2
Thomas, S.3
Raha, P.4
Lacevic, M.5
Miller, A.6
|